ACADIA Pharmaceuticals Inc.
ACAD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.75 | -0.42 | 0.02 | 0.00 |
| FCF Yield | 4.49% | -2.83% | 1.31% | 2.47% |
| EV / EBITDA | 85.12 | 117.31 | 228.51 | 77.33 |
| Quality | ||||
| ROIC | 2.34% | 1.57% | 17.06% | 4.16% |
| Gross Margin | 92.16% | 91.65% | 91.60% | 92.47% |
| Cash Conversion Ratio | 1.03 | 2.40 | 1.07 | 0.28 |
| Growth | ||||
| Revenue 3-Year CAGR | 18.34% | 22.75% | 24.18% | 22.80% |
| Free Cash Flow Growth | 306.96% | -296.64% | -36.80% | 152.57% |
| Safety | ||||
| Net Debt / EBITDA | -4.91 | -7.27 | -21.93 | -3.34 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.79 | 0.89 | 0.99 | 0.31 |
| Cash Conversion Cycle | 66.88 | 63.31 | 60.06 | 235.56 |